StocksMedium•6 November 2026•
1 min read
Elanco Raises 2026 Guidance After 11% Revenue Growth in Q3
Key Facts
1Elanco reported Q3 revenue of $1.265 billion, an 11% increase year-over-year.
2The company raised its full-year 2026 adjusted EPS guidance to a range of $1.17 to $1.20.
3The company achieved a net leverage ratio milestone of 2.9x adjusted EBITDA.
Elanco Animal Health reported Q3 2026 revenue of $1.265 billion, marking an 11% increase compared to the same period last year. According to a PR Newswire statement, the company raised its full-year 2026 adjusted EPS guidance to a range of $1.17 to $1.20. Additionally, the firm reached a net leverage ratio milestone of 2.9x adjusted EBITDA.
ELAN closed at $23.68 on November 5, 2026, with the stock trading between a low of $23.43 and a high of $25.24 during that session. The financial performance was driven by accelerated pricing and organic constant currency revenue growth, alongside successful innovation delivery that supported gross margin expansion.